Letaplimab represents a significant step in the battle against complement-induced diseases. This unique monoclonal antibody targets C3b, a essential component of the immune cascade, offering a anticipated way to reduce https://tessaeer491438.pointblog.net/letaplimab-a-hopeful-new-therapy-92306747